Last reviewed 2026-04-20 · How we verify

Zebeta (BISOPROLOL)

Zebeta (Bisoprolol) is a beta-adrenergic blocker, a small molecule that targets the beta-1 adrenergic receptor. It is used to treat atrial fibrillation and hypertensive disorders. Originally developed by TEVA WOMENS, it is now owned by Teva Branded Pharm and has been off-patent since its FDA approval in 1992. Zebeta is available as a generic medication from multiple manufacturers. As a beta-blocker, it is essential to monitor patients for signs of bradycardia, hypotension, and worsening heart failure.

At a glance

Approved indications

• Atrial fibrillation
• Hypertensive disorder

Common side effects

• increased sweating
• arthralgia
• dizziness
• headache
• hypoaesthesia
• dry mouth
• bradycardia
• vivid dreams
• insomnia
• depression
• diarrhea
• nausea

Drug interactions

• chlorpropamide
• cimetidine
• disopyramide
• epinephrine
• felodipine
• glibenclamide
• glipizide
• indomethacin
• piroxicam
• sulindac
• tolazamide
• tolbutamide

Key clinical trials

• Blood Flow Restricted Resistance Exercises Versus Low Level Laser on Cardiac Functions in Patients With Chronic Heart Failure (NA)
• Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy (NA)
• Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes (NA)
• Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF) (PHASE4)
• MEdical Treatment in Idiopathic Ventricular Fibrillation Patients (PHASE4)
• The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction (PHASE4)
• Beta-blOckers discoNtinuation in Patients Presenting Heart FaIlure With REcovered Left Ventricular Ejection Fraction (PHASE3)
• Rate Control in Patients With Atrial Fibrillation (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.